DGK and DZHK position paper on genome editing: basic science applications and future perspective

Author:

Brandes Ralf P.ORCID,Dueck Anne,Engelhardt Stefan,Kaulich Manuel,Kupatt Christian,De Angelis Maria Teresa,Leisegang Matthias S.,le Noble Ferdinand,Moretti Alessandra,Müller Oliver J.,Skryabin Boris V.,Thum Thomas,Wurst Wolfgang

Abstract

AbstractFor a long time, gene editing had been a scientific concept, which was limited to a few applications. With recent developments, following the discovery of TALEN zinc-finger endonucleases and in particular the CRISPR/Cas system, gene editing has become a technique applicable in most laboratories. The current gain- and loss-of function models in basic science are revolutionary as they allow unbiased screens of unprecedented depth and complexity and rapid development of transgenic animals. Modifications of CRISPR/Cas have been developed to precisely interrogate epigenetic regulation or to visualize DNA complexes. Moreover, gene editing as a clinical treatment option is rapidly developing with first trials on the way. This article reviews the most recent progress in the field, covering expert opinions gathered during joint conferences on genome editing of the German Cardiac Society (DGK) and the German Center for Cardiovascular Research (DZHK). Particularly focusing on the translational aspect and the combination of cellular and animal applications, the authors aim to provide direction for the development of the field and the most frequent applications with their problems.

Funder

Deutsches Zentrum für Herz-Kreislaufforschung

Deutsche Gesellschaft für Kardiologie-Herz und Kreislaufforschung.

Projekt DEAL

Publisher

Springer Science and Business Media LLC

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine,Physiology

Reference173 articles.

1. (2017) Gene therapy clinical trials worldwide. Provided by the Journal of Gene Medicine. http://www.abedia.com/wiley/. Accessed 14 Apr 2020

2. (2018) NCT03655678: A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia. https://clinicaltrials.gov/ct2/show/NCT03655678. Accessed 14 Apr 2020

3. (2019) NCT03745287: A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease. https://clinicaltrials.gov/ct2/show/NCT03745287. Accessed 14 Apr 2020

4. (2019) NCT03872479: Single Ascending Dose Study in Participants With LCA10. https://clinicaltrials.gov/ct2/show/NCT03872479. Accessed 14 Apr 2020

5. Abudayyeh OO, Gootenberg JS, Essletzbichler P, Han S, Joung J, Belanto JJ, Verdine V, Cox DBT, Kellner MJ, Regev A, Lander ES, Voytas DF, Ting AY, Zhang F (2017) RNA targeting with CRISPR-Cas13. Nature 550:280–284. https://doi.org/10.1038/nature24049

Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3